Bluebird Bio Inc. and privately held Gritstone Oncology Inc. said they plan to collaborate in a broad cancer cell therapy R&D and commercialization pact involving 10 tumor-specific targets across multiple tumor types and, in certain cases, T-cell receptors (TCRs) directed to those targets.